Hepatocellular carcinoma (HCC) is a malignancy with high incidence and poor prognosis. Most patients with HCC are diagnosed at an intermediate-advanced stage, losing the opportunity for surgical resection. Although transcatheter arterial chemoembolization (TACE) is recommended for intermediate-advanced stage HCC, supported by evidence from multiple randomized controlled trials, its efficacy is often limited by high-risk factors such as large tumor burden, vascular tumor thrombosis, arteriovenous shunting, or infiltrative growth pattern. In recent years, accumulating evidence has established hepatic arterial infusion chemotherapy (HAIC) as an effective treatment for intermediate-advanced stage HCC, especially in patients with these high-risk features, as it can significantly enhance local tumor control and prolong survival. Recent studies and clinical practice have demonstrated that TACE and HAIC, as two effective intra-arterial therapies, possess distinct mechanisms of action. Their rational combination allows for technical complementarity, yielding a synergistic anti-tumor effect and further improving outcomes in high-risk patients with intermediate-advanced stage HCC. In this context, based on relevant literature and clinical experience, this article discusses the theoretical rationale, technical essentials, appropriate patient selection, and clinical evidence for combining TACE with HAIC in the treatment of HCC, aiming to provide references for its standardized application and wider clinical adoption.
ObjectiveTo summarize the research progress and clinical efficacy of hepatic artery infusion chemotherapy in the treatment of colorectal cancer liver metastasis.MethodThe literatures of hepatic artery infusion chemotherapy for colorectal cancer liver metastasis were collected and reviewed.ResultsThe incidence of colorectal cancer liver metastasis was high, which affected the prognosis of patients. Surgical treatment was the preferred treatment for colorectal cancer liver metastasis. Hepatic arterial infusion chemotherapy could be used for preoperative neoadjuvant therapy and postoperative adjuvant therapy.ConclusionsHepatic arterial infusion chemotherapy is an effective local treatment for colorectal cancer liver metastasis and can be used as a supplement to surgical treatment. Compared with systemic chemotherapy, hepatic arterial infusion chemotherapy combined with systemic chemotherapy can improve the overall survival and disease-free survival, reduce the risk of intrahepatic recurrence, and improve the prognosis of patients.
ObjectiveTo exploring the technical feasibility and safety of transradial sheathless microcatheter- hepatic arterial infusion chemotherapy (TRSM-HAIC) for malignant liver tumors. MethodsThe clinical data of patients with malignant liver tumors who underwent TRSM-HAIC in the Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, from November 2025 to March 2026, were retrospectively collected. The recorded parameters included procedural core metrics (such as puncture success rate, technical success rate, total procedure time), perioperative complications (according to CIRSE classification), postoperative recovery outcomes (immobilization time, hospital stay), and radial artery patency. ResultsA total of 20 patients underwent 36 sessions of TRSM-HAIC. The 36 sessions of TRSM-HAIC performed on 20 patients were all completed successfully. Both the puncture success rate and the technical success rate reached 100%, with no case requiring conversion to an alternative access route. The total procedure time was (40.5±12.8) min, with a median of 38.0 min. The median time from puncture to successful microcatheter placement in the hepatic artery was 4.5 min. During the perioperative period, only one minor puncture site hematoma (CIRSE grade 1 complication) was observed. No complications such as severe hemorrhage, hematoma, vascular spasm, dissection, or thrombosis occurred. No strict immobilization was required postoperatively and the postprocedural hospital stay was (4.5±1.2) d, with a median of 4 d. All 12 patients who required repeat treatment chose to continue with this method, and no new vascular complications arose during subsequent sessions. All patients maintained radial artery patency after the procedure. ConclusionsTRSM-HAIC is a safe and feasible innovative interventional technique. Its advantages include a 100% technical success rate, a low complication rate, and rapid postoperative recovery, providing a new minimally invasive option for malignant liver tumors. This is particularly relevant for patients requiring multiple interventional therapies or those unable to tolerate prolonged immobilization. Its long-term vascular protective effect and oncological outcomes warrant further validation in larger cohorts with extended follow-up.
